Accendra Health reports Q1, announces $1.5B optimization
By HME News Staff
Updated 8:39 AM CDT, Mon May 11, 2026
RICHMOND, Va. – Accendra Health reported $627.8 million for the first quarter of 2026 vs. $673.9 million for the same period last year. Adjusted EBITDA was $58.4 million vs. $96 million.
Unless otherwise noted, the results reflect Accendra’s continuing operations, which represent what was previously the Patient Direct segment and certain functional operations. The company ended the fourth quarter of 2025 by selling its Products & Healthcare Services (P&HS) business to Platinum Equity for $375 million, and rebranding as Accendra Health.
“Our first quarter results were aligned with our expectations as we continue our transformation into a pure play home based care company,” said Edward Pesicka, president & CEO. “We are also pleased to report that transition services and other separation activity related to our divestiture of Owens & Minor are on track and going according to schedule.”
Accendra also announced a more than $1.5 billion comprehensive balance sheet optimization transaction with commitments from existing creditors that the company says will strengthen the balance sheet, significantly extend maturities and reduce total leverage.
Comments